A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology
Scott C. Jeffrey(Seagen (United States)), Peter D. Senter(North Carolina Central University), David E. Thurston(King's College London), Weiping Zeng(Seagen (United States)), Django Sussman(Seagen (United States)), Che‐Leung Law(Seagen (United States)), David W. Meyer(Seagen (United States)), Robert P. Lyon(Seagen (United States)), Luke A. Masterson(Spirogen (United Kingdom)), Jamie B. Miyamoto(Seagen (United States)), Martha E. Anderson(Seagen (United States)), Arnaud Tiberghien(Spirogen (United Kingdom)), Nicole D. Nicholas(Seagen (United States)), Ivan J. Stone(Seagen (United States)), Stephen J. Gregson(Spirogen (United Kingdom)), Philip W. Howard(Spirogen (United Kingdom)), Russell J. Sanderson(Seagen (United States)), Joshua H. Hunter(Seagen (United States)), Nicole M. Okeley(Seagen (United States)), Chris Leiske(Seagen (United States)), Patrick Burke(Seagen (United States))
Cited by 246
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772